A mid-regional pro-adrenomedullin fragment (MR-proADM) was identified in sepsis patient plasma as a stable, measurable surrogate for adrenomedullin — laying the groundwork for what became a major clinical sepsis biomarker.
Key findingA mid-regional pro-adrenomedullin (MR-proADM) fragment was identified and quantified in sepsis patient plasma, providing a stable, measurable surrogat
What the researchers found
A mid-regional pro-adrenomedullin (MR-proADM) fragment was identified and quantified in sepsis patient plasma, providing a stable, measurable surrogate for the unstable mature adrenomedullin — establishing the basis for clinical MR-proADM sepsis testing.
Why it matters
Relevant for neuropeptides, cardiovascular, clinical-trials.
How the study worked
clinical-trial study on neuropeptides, cardiovascular.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2004.
The bigger picture
Advances peptide therapeutics/biomarker research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients.
Peptides, 25(8), 1369-72
Citation
Struck, Joachim; Tao, Chen; Morgenthaler, Nils G; Bergmann, Andreas. (2004). Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients.. Peptides, 25(8), 1369-72.